Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke

• Published in: Stroke (1970) Vol. 42; no. 9; pp. 2633 - 2635
• Main Authors: SWITZER, Jeffrey A, HESS, David C, ERGUL, Adviye, WALLER, Jennifer L, MACHADO, Livia S, PORTIK-DOBOS, Vera, CREED PETTIGREW, L, CLARK, Wayne M, FAGAN, Susan C
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 01-09-2011
• Subjects: Aged; Anti-Bacterial Agents - administration & dosage; Biological and medical sciences; Blood. Blood coagulation. Reticuloendothelial system; Brain Ischemia - blood; Brain Ischemia - drug therapy; Female; Fibrinolytic Agents - administration & dosage; Humans; Infusions, Intravenous; Male; Matrix Metalloproteinase 9 - blood; Matrix Metalloproteinase Inhibitors; Medical sciences; Middle Aged; Minocycline - administration & dosage; Neurology; Pharmacology. Drug treatments; Stroke - blood; Stroke - drug therapy; Thrombolytic Therapy - methods; Tissue Plasminogen Activator - administration & dosage; Vascular diseases and vascular malformations of the nervous system; Cerebral infarction; Stroke; Nervous system diseases; Intravenous administration; Enzyme; Tetracycline derivatives; Metalloendopeptidases; Cardiovascular disease; Inflammation; Gelatinase B; Cerebral disorder; Vascular disease; Peptidases; Antibiotic; acute stroke; neuroprotection; Central nervous system disease; Brain ischemia; Minocycline; Hydrolases; Protein synthesis inhibitor; Antibacterial agent; Cerebrovascular disease
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/STROKEAHA.111.618215

Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage.
The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group.
Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019).
Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.